New heartburn drug candidate tested for heart safety in healthy volunteers

NCT ID NCT05469854

First seen Jun 18, 2026 · Last updated Jun 22, 2026 · Updated 1 time

Summary

This Phase 1 trial is testing a new drug called linaprazan glurate in 121 healthy adults to see how the body absorbs and processes it, and whether it affects heart rhythm. The study is double-blind and placebo-controlled, meaning some participants get a dummy pill. It is an early step to gather safety data before testing the drug in people with GERD (chronic acid reflux).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY, AND TOLERABILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CTC Clinical Trial Consultants AB

    RECRUITING

    Uppsala, SE-75237, Sweden

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

linaprazan glurate

What this could lead to

If successful, this trial could help determine safe dosing and heart safety for a potential new GERD treatment.

What could go wrong

This is an early Phase 1 study in healthy people, not patients. It only tests safety and drug processing, not whether it works for GERD. Results may not predict effectiveness.

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.